Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Eisai

101 clinical trials

13 abstracts

Clinical trial
An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2019-10-31
Clinical trial
An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas - INSTAL-101
Status: Terminated, Estimated PCD: 2022-07-26
Clinical trial
A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Status: Completed, Estimated PCD: 2023-10-26
Clinical trial
An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
Status: Active (not recruiting), Estimated PCD: 2018-07-19
Clinical trial
A Phase 1 Study of H3B-6545 in Japanese Women With Estrogen Receptor-positive, HER2 Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2022-09-16
Clinical trial
A First-in-Human, Single Ascending Dose and Pharmacokinetic/Pharmacodynamic Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2025 in Healthy Subjects
Status: Completed, Estimated PCD: 2024-01-30
Clinical trial
A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
Status: Active (not recruiting), Estimated PCD: 2020-02-14
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome
Status: Recruiting, Estimated PCD: 2025-03-05
Clinical trial
A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan
Status: Recruiting, Estimated PCD: 2028-03-31
Clinical trial
A Multicentre, Observational, Phase 4 Study to Evaluate the Safety and Tolerability of Lenvatinib in Patients With Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)
Status: Active (not recruiting), Estimated PCD: 2031-03-07
Clinical trial
An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 Years of Age With Epilepsy
Status: Completed, Estimated PCD: 2022-08-23
Clinical trial
An Open-label Phase 1 Study of E7386 in Subjects With Advanced Solid Tumor Including Colorectal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
Post-marketing Observational Study of Remitoro® Intravenous Injection 300 μg - Safety of Remitoro in Patients With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Status: Completed, Estimated PCD: 2023-03-17
Clinical trial
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials
Status: Completed, Estimated PCD: 2023-12-21
Clinical trial
An Open-label Phase 1b Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Status: Recruiting, Estimated PCD: 2027-03-15
Clinical trial
A First-In-Human, Two-Part Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Subjects
Status: Completed, Estimated PCD: 2024-01-18
Clinical trial
A Phase 1 Study of E7130 in Subjects With Solid Tumor
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-human Epidermal Growth Factor Receptor 2 (Anti-HER2) Antibody-drug Conjugate (ADC), in Previously Treated Subjects With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Status: Recruiting, Estimated PCD: 2026-10-26
Clinical trial
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
Status: Recruiting, Estimated PCD: 2029-02-15
Clinical trial
A Prospective, Non-Interventional, Observational, Multicenter Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Adjunctive Therapy in the Routine Clinical Care of Subjects >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
Status: Completed, Estimated PCD: 2023-01-12
Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Pharmacodynamics of Lemborexant in Korean Subjects With Insomnia Disorder
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
An Open-Label Study With Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy
Status: Recruiting, Estimated PCD: 2024-10-06
Clinical trial
An Open Label Phase I Dose Escalation Study Of E7080
Status: Completed, Estimated PCD: 2009-06-19
Clinical trial
An Open-Label, Single Center, Randomized, Pharmacoscintigraphic Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release Tablets Compared to an E7386 Immediate Release Tablet in Healthy Adult Subjects
Status: Withdrawn, Estimated PCD: 2023-05-17
Clinical trial
A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E8001 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2023-08-18
Clinical trial
A Single and Multiple Dose Pharmacokinetic Study of Dotinurad in Chinese Healthy Subjects
Status: Completed, Estimated PCD: 2022-12-13
Clinical trial
INO01T
Status: Completed, Estimated PCD: 2022-11-02
Clinical trial
An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial-Onset Seizures or Primary Generalized Tonic Clonic Seizures
Status: Completed, Estimated PCD: 2019-02-05
Clinical trial
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer
Status: Completed, Estimated PCD: 2012-12-26
Clinical trial
A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Status: Completed, Estimated PCD: 2021-12-17
Clinical trial
Protocol for Study EQF01S: General Drug Use-Results Observational Study of Equfina® TABLETS 50 mg Observational Study on the Incidences of Adverse Drug Reactions in Patients With Parkinson's Disease (Including Patients With Hepatic Impairment)
Status: Completed, Estimated PCD: 2022-10-13
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2011-08-01
Clinical trial
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Status: Completed, Estimated PCD: 2021-12-06
Clinical trial
E7389-G000-302
Status: Completed, Estimated PCD: 2014-05-30
Clinical trial
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
Status: Completed, Estimated PCD: 2013-03-01
Clinical trial
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Completed, Estimated PCD: 2013-04-30
Clinical trial
A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals
Status: Completed, Estimated PCD: 2013-04-01
Clinical trial
A Phase 1 Open-Label, Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2011-09-01
Clinical trial
An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Patients
Status: Completed, Estimated PCD: 2023-09-04
Clinical trial
Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Status: Completed, Estimated PCD: 2019-07-18
Clinical trial
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125.
Status: Terminated, Estimated PCD: 2012-02-01
Clinical trial
An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology
Status: Completed, Estimated PCD: 2021-12-08
Clinical trial
An Open-Label, Multicenter, Phase 1 Study of E7386 in Subjects With Selected Advanced Neoplasms
Status: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Phase III, Randomized, Open-label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Flexible Bronchoscopy Procedures
Status: Terminated, Estimated PCD: 2005-03-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2814 in Healthy Subjects
Status: Completed, Estimated PCD: 2023-03-09
Clinical trial
A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2017-07-12
Clinical trial
An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome
Status:
Clinical trial
Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
Status: Completed, Estimated PCD: 2015-10-14
Clinical trial
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Completed, Estimated PCD: 2012-11-01
Clinical trial
An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma
Status: Completed, Estimated PCD: 2013-03-19
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of the Efficacy and Safety of Lemborexant in Chinese Subjects With Insomnia Disorder
Status: Completed, Estimated PCD: 2023-03-17
Clinical trial
A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2022-12-28
Clinical trial
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2020-10-26
Clinical trial
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2027-09-15
Clinical trial
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-02-20
Clinical trial
Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
Status: Completed, Estimated PCD: 2015-01-01
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
Status: Completed, Estimated PCD: 2013-03-01
Clinical trial
Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies
Status:
Clinical trial
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
Status: , Estimated PCD: 2011-08-01
Clinical trial
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Status: Completed, Estimated PCD: 2012-03-01
Clinical trial
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer
Status: Completed, Estimated PCD: 2011-04-07
Clinical trial
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
Phase I Dose-Finding Study of E7070 in Combination With Irinotecan
Status: Completed, Estimated PCD: 2013-03-01
Clinical trial
A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Completed, Estimated PCD: 2017-03-31
Clinical trial
An Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects
Status: Completed, Estimated PCD: 2008-12-01
Clinical trial
An Open-label, Multi-centre, Multi-national Post-marketing Non-interventional Observational Study of the Use of Zonisamide (ZNS) in the Adjunctive Treatment of Adult Patients With Partial Onset Seizures Treated With One Antiepileptic Drug (AED) as Baseline Medication
Status: Completed, Estimated PCD: 2013-06-01
Clinical trial
A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors
Status: Completed, Estimated PCD: 2022-10-26
Clinical trial
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820, to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
Status: Completed, Estimated PCD: 2014-04-30
Clinical trial
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Completed, Estimated PCD: 2013-03-01
Clinical trial
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
Status: Completed, Estimated PCD: 2016-05-01
Clinical trial
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Completed, Estimated PCD: 2012-05-01
Clinical trial
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status: Completed, Estimated PCD: 2020-08-18
Clinical trial
A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Status: Completed, Estimated PCD: 2021-01-07
Clinical trial
An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Status: Terminated, Estimated PCD: 2011-02-18
Clinical trial
PERPRISE: A Prospective Non-interventional Study Evaluating the Effectiveness of Perampanel (Fycompa®) as Only Add-on Treatment in Patients With Primary or Secondarily Generalized Tonic-clonic Seizures
Status: Completed, Estimated PCD: 2023-03-31
Clinical trial
An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2025-07-14
Clinical trial
An Open-label Phase 1b Study of E7090 Monotherapy and in Combination With Other Anticancer Agents in Subjects With ER+, HER2- Recurrent/Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Subjects With Moderate to Severe Obstructive Sleep Apnea and Adult and Elderly Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status: Completed, Estimated PCD: 2022-02-10
Clinical trial
A Phase II, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Colonoscopy Procedures
Status: Terminated
Clinical trial
A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout
Status: Completed, Estimated PCD: 2023-06-14
Clinical trial
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosarcoma (OLIE)
Status: Completed, Estimated PCD: 2022-06-22
Clinical trial
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Terminated, Estimated PCD: 2015-06-22
Clinical trial
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2012-12-31
Clinical trial
An Open-Label, Single-Center, 2-Part, Parallel Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of [14C]E7386 in Healthy Male Subjects
Status: Completed, Estimated PCD: 2023-08-31
Clinical trial
An Extended Access Program (EAP) for Perampanel
Status:
Clinical trial
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2015-07-01
Clinical trial
An Open-Label, Parallel-Group, Randomized Study to Demonstrate the Bioequivalence of the Subcutaneous Formulation of Lecanemab Supplied in Vials and a Single-Use Auto-Injector
Status: Completed, Estimated PCD: 2023-01-06
Clinical trial
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)
Status: Active (not recruiting), Estimated PCD: 2020-08-28
Clinical trial
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Status: Completed, Estimated PCD: 2015-01-02
Clinical trial
A Phase 1 Study of E7080 in Subjects With Solid Tumor
Status: Completed, Estimated PCD: 2011-12-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Completed, Estimated PCD: 2013-11-15
Clinical trial
A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Completed, Estimated PCD: 2014-03-01
Clinical trial
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Status: Completed, Estimated PCD: 2021-11-02
Clinical trial
A Multicenter, Open-Label, Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR 2 Gene Fusion
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors
Status: Recruiting, Estimated PCD: 2025-09-30
Abstract
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Org: Memorial Sloan Kettering Cancer Center, Kyushu University, University Hospital Essen, P.A. Herzen Moscow Oncological Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
Org: Kanagawa Cancer Center, Fukushima Medical University, School of Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), National Cancer Center Hospital East, Kashiwa, Japan, Department of Breast Surgery, Shizuoka General Hospital,
Abstract
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,
Abstract
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
Org: Royal Marsden NHS Foundation Trust, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Eisai,
Abstract
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).
Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Mayo Clinic, Miami Cancer Institute, Baptist Health South Florida, NW Medical Specialties,
Abstract
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
Org: Sarah Cannon Research Institute/Tennessee Oncology, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Royal Marsden NHS Foundation Trust, Lineberger Comprehensive Cancer Center,
Abstract
Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial.
Org: University Hospital Essen, Memorial Sloan Kettering Cancer Center, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Department of Urology and Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany, Medical University of Vienna,
Abstract
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
Org: Sutter/California Pacific Medical Center, Marqués de Valdecilla University Hospital, IDIVAL, The Chinese University of Hong Kong, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”,
Abstract
Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
Org: University of Michigan, Cancer Research and Biostatistics (CRAB), Seattle, WA, Eisai, Biovica International AB, American Society of Clinical Oncology,
Abstract
Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.
Org: Kurume University Hospital, Kanagawa Cancer Center, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, National Hospital Organization Kinki-Chuo Medical Center, Osaka International Cancer Institute, Osaka, Japan,
Abstract
Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.
Org: Imperial College, University Medical Center Mainz, Mtech Access, Eisai, UCLA Medical Center,
Abstract
Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers.
Org: Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, Eisai, Exton, School of Clinical Sciences at Monash Health,
Abstract
Prospective observational study to evaluate lemborexant utility in insomnia among women with breast cancer (WJOG14921B, LUNAR study).
Org: Breast Medical Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, The Cancer Institute Hospital of JFCR, Tokyo, Japan, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Gifu University Hospital, International University of Health and Welfare Narita Hospital, Narita, Japan,
Clinical trial
A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1
Status: Not yet recruiting, Estimated PCD: 2025-02-14
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Combined Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Single Dose Study to Assess Food Effect of E2086 in Healthy Adult Subjects
Status: Not yet recruiting, Estimated PCD: 2024-10-16